Marina Biotech, Inc. (OTCMKTS:MRNA) Surging On News

[[tagnumber 0]][[tagnumber 1]]Marina Biotech, Inc. (OTCMKTS:MRNA) rarely seems some action and it has already been established that it has some liquidity issues. This year wasn’t really good for the company stock, as it was slowly sliding down the charts.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]MRNA[[tagnumber 7]] certainly got to a level that was low for an OTC biotech company. The company stock’s value dropped below $10 million quite a while back, while the balance sheet didn’t look all that terrible. Here are some of the numbers that were contained in the company’s annual report.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 11]] [[tagnumber 12]]cash: $710 thousand[[tagnumber 13]] [[tagnumber 12]]current assets: $850 thousand[[tagnumber 13]] [[tagnumber 12]]current liabilities: $2.43 million[[tagnumber 13]] [[tagnumber 12]]annual revenues: $680 thousand[[tagnumber 13]] [[tagnumber 12]]loss from operations: $3.98 million[[tagnumber 13]] [[tagnumber 22]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Those numbers aren’t all that bad, but [[tagnumber 6]]MRNA[[tagnumber 7]] still gets really little attention. Yesterday the company made a couple of press releases that shined the spotlight on the ticker. Firstly, they announced that [[tagnumber 6]]MRNA[[tagnumber 7]] has terminated the negotiations for the sale of its nucleic acid therapeutic assets to Microlin Bio.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Then the company announced that it will acquire the intranasal ketamine program of the infamous Turing Pharmaceuticals AG, the privately held entity that Martin Shkreli founded in February 2015. The company was controversial with its 5,556% hike of the antiparasitic drug Daraprim before Shkreli got arrested by the FBI and charged with securities fraud and had to resign from the positions of CEO.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The news caused [[tagnumber 6]]MRNA[[tagnumber 7]] to surge 64.47% in value yesterday and we saw the ticker close at 25 cents per share. The volume was more than fifteen times the 30–day average and the 3.47 million shares that changed their owners generated $1.13 million in daily trade value.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]After a shaky start of today’s session we see that [[tagnumber 6]]MRNA[[tagnumber 7]] is 6% up as of the writing of this article, but you should still be sure to do your due diligence and weigh out the risks before putting any money on the line.[[tagnumber 2]]